阿替利珠单抗重新使用伴发肺结节病样反应。
Recommencement of atezolizumab with associated pulmonary sarcoid-like reaction.
作者信息
Tam Khai, Wallace Michael, Mulrennan Siobhain
机构信息
Respiratory and Hepatology Department Sir Charles Gairdner Hospital Perth Western Australia Australia.
出版信息
Respirol Case Rep. 2024 Apr 26;12(5):e01363. doi: 10.1002/rcr2.1363. eCollection 2024 May.
An 81 year old male with Child-Pugh A cirrhosis and metastatic hepatocellular carcinoma (HCC) treated with 3-weekly atezolizumab and bevacizumab developed a pulmonary sarcoid-like reaction (SLR) after 5 months. Atezolizumab, an immune checkpoint inhibitor, was identified as the likely culprit. He was treated with prednisolone, resulting in improvement, and was successfully rechallenged with both atezolizumab and bevacizumab.
一名81岁男性，患有Child-Pugh A级肝硬化和转移性肝细胞癌（HCC），接受每3周一次的阿替利珠单抗和贝伐单抗治疗，5个月后出现了肺结节病样反应（SLR）。免疫检查点抑制剂阿替利珠单抗被确定为可能的病因。他接受了泼尼松龙治疗，症状得到改善，并成功地再次接受了阿替利珠单抗和贝伐单抗治疗。
Zotero 插件